300685 Amoy Diagnostics
- 17.51
- -0.42-2.34%
Amoy Diagnostics News
Express News | Announcement at noon: Jinwo Shareholder voluntarily promises not to reduce the company's shareholding.
Express News | Amoy Diagnostics: Signed a Companion Diagnostic Collaboration Agreement with Roche.
Amoy Diagnostics Gets Certificate to Register PCR Analyzer
Amoy Diagnostics (SHE:300685) obtained a medical device registration certificate from China's National Medical Products Administration for its real-time fluorescence quantitative PCR analyzer also kno
Amoy Diagnostics (300685.SZ): The company's overseas markets focus on East Asia, Europe, Southeast Asia and other markets.
Amoy Diagnostics (300685.SZ) stated on the investor platform that the company's overseas market is currently focused on East Asia, Europe, Southeast Asia, and other markets. The company's production and operation have been stable and orderly, and the management will continue to do a good job in various tasks such as operation and management, insisting on sustainable and profitable growth, and creating value for society and shareholders.
Ed Biotech (300685.SZ) plans to pay 1.5 yuan for 10 shares to be deducted from interest on May 30
Ed Biotech (300685.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Express News | Ed Biotech: Signed a cooperation agreement with Boehringer Ingelheim to accompany diagnosis
Ed Biotech (300685): Net profit deducted from non-return to mother increased 26% year-on-year in the first quarter, consolidating the leading position in the industry
Revenue for the first quarter of 2024 increased 19.5% year over year, and net profit to mother after deducting equity incentive expenses and non-recurring profit and loss performed well. Q1 2024:233 million (+19.53%), net profit of 0.6 million to mother
Ed Biotech (300685): Domestic share is expected to increase and accelerate overseas market development
Guide to this report: Equity incentive costs are dragging down the apparent profit growth rate. The performance is in line with expectations. The domestic market compliance advantages are prominent, the international market is expanding rapidly, and the pharmaceutical company's circle of friends continues to grow rapidly. Maintain an increase in holdings rating. Key investment points: maintenance
Ed Biotech (300685): Leading companies in the regulatory development and compliance of the oncology genetic testing industry benefit from many parties
Incident: The company released its 2023 annual report, achieving operating income of 1,044 million yuan (+23.91%), net profit to mother of 261 million yuan (-0.86%), and net profit of non-return to mother of 239 million yuan (+52.
Ed Biotech (300685): First quarter results are in line with expectations, optimistic about the release of innovative products
Event: The company released its report for the first quarter of 2024, and achieved operating income of 233 million yuan (+19.53%) and net profit to mother of 64 million yuan (+12.01%) in the first quarter of 2024.
Ed Biotech (300685): Performance has achieved steady growth, and the new product layout is expected to accelerate
Event: The company publishes its report for the first quarter of 2024. In the first quarter of 2024, the company achieved operating income of 233 million yuan, a year-on-year increase of 19.53%; realized net profit to mother of 64 million yuan, an increase of 12.01 million yuan over the previous year
Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hos
Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hospital market is stable; 2) the accelerated transformation of testing to in-hospital, domestic and international two-wheel drive; 3) gross margin is rising steadily, and the scale effect continues to be prominent in the new industry environment. (Mainichi Keizai Shimbun)
Ed Biotech (300685): Revenue increased 38% year-on-year in the fourth quarter, and insisted on using the hospital market as the main track
Revenue surpassed 1 billion for the first time, and the leading position in the hospital market is stable. 2023 revenue of $1,044 million (+23.91%), net profit attributable to mother of $261 million (-0.86%), net profit of non-return to mother of $239 million
Ed Biotech (300685): Performance is in line with expectations, and compliance advantages are highlighted
Guide to this report: The performance is in line with expectations, domestic market compliance advantages are prominent, in-hospital reagent revenue is growing rapidly, the rapid expansion of the international market accelerates market entry, and the pharmaceutical companies' circle of friends continues to grow rapidly, and it is expected that it will continue to grow rapidly. Maintain an increase in holdings rating. Key investment points
Ed Biotech (300685.SZ): PD-L1 products have completed pre-testing and admission work in more than 100 hospitals
Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “layout of the company's products on the immunohistochemistry platform,” the company replied that the company's immunohistochemical products focus on CDx (such as c-Met, HER2, Claudin18.2, etc.), which also cover routine immunohistochemical targets for common tumors, and have automated dyeing machines and self-produced secondary reagents and supporting reagents. PD-L1 products have completed pre-testing and admission work in more than 100 hospitals, helping the company develop the immunohistochemistry market
Ed Biotech (300685.SZ): The MSI test kit is the first pan-solid tumor immunotherapy companion diagnosis approved for marketing in China
Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “status of newly approved MSI products,” the company replied that tumor immunotherapy is increasingly becoming an important treatment for precision cancer treatment. MSI and PDL1 (the company's PD-L1 product was approved and marketed by the NMPA in March 2022) are currently the most clinically recognized biomarkers for predicting the efficacy of immunopharmaceuticals. The company's MSI test kit is the first pan-solid tumor immunotherapy companion diagnosis approved for marketing in China. In 2024, rapidly advance MSI product pre-emption
Ed Biotech (300685.SZ): PCR-11 gene, IDH, Her2/er/PR products are under NMPA approval
Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “stock status of the company's new products,” the company replied that the company's PCR-11 gene, IDH, HER2/ER/PR products are under NMPA approval, and HRD products are applying for innovative medical devices; in addition, approval for various tumor associated diagnostic products is progressing rapidly.
Ed Biotech (300685): Annual results exceeded expectations and accelerated development of domestic and foreign markets
Incident: The company released its 2023 annual report. The company achieved revenue of 1,044 billion yuan (+23.91%), net profit to mother of 261 million yuan (-0.86%), and deducted non-net profit of 239 million yuan in 2023
Ed Biotech (300685): Contrary to the trend, the performance exceeded expectations
Growing against the trend, the leading position in the industry was further stabilized. In 2023, the company achieved total revenue of 1,044 billion yuan, an increase of 23.91% over the previous year. The growth rate was relatively fast. The company simultaneously expanded the domestic hospital market and the country in 2023
Ed Biotech (300685.SZ): Net profit for 2023 decreased by 0.86% to 261 million yuan, plans to pay 10 to 1.5 yuan
On April 15, Ge Longhui (300685.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,044 million yuan, up 23.91% year on year; net profit attributable to shareholders of listed companies was 261 million yuan, down 0.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 239 million yuan, up 52.21% year on year; basic income per share was 0.66 yuan; it plans to distribute a cash dividend of 1.5 yuan (tax included) to all shareholders for every 10 shares.
Analysis
Price Target
No Data
